Medicare Enrolled
Dr. Kathryn Bollin, M.D.
Medical Oncology · San Diego, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Bollin from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bollin?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Bollin
Dr. Kathryn Bollin is a medical oncology specialist in San Diego, CA, with 16 years of NPI registration. Based on federal Medicare data, Dr. Bollin performed 15,634 Medicare services across 632 unique beneficiaries.
Between the years covered by Open Payments, Dr. Bollin received a total of $8,163 from 68 pharmaceutical and/or device companies across 394 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Bollin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years in practice
▲ Top 18% volume in CA
$8,163 industry payments
Medicare Practice Summary
Medicare Utilization ↗15,634
Medicare services
Top 18% in CA for medical oncology
632
Unique beneficiaries
$46
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~977 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 14,401 | $42 | $171 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
528 | $106 | $350 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
147 | $65 | $248 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
121 | $120 | $479 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
102 | $14 | $55 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
78 | $146 | $491 |
| New patient office visit, complex (60-74 min) | 72 | $181 | $598 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
48 | $98 | $269 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
26 | $58 | $236 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
24 | $100 | $355 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
22 | $64 | $249 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
21 | $1 | $41 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
15 | $11 | $44 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
15 | $143 | $520 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
14 | $141 | $453 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.1% high complexity
92.8% medium
6.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$8,163
Total received (2018-2024)
Avg $1,166/year across 7 years
Top 39% in CA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
68
Companies
394
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,014 (98.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$149 (1.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,527
2023
$996
2022
$447
2021
$359
2020
$822
2019
$1,613
2018
$2,399
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$179
ViiV Healthcare Company
$168
Novartis Pharmaceuticals Corporation
$159
ABBVIE INC.
$141
Regeneron Pharmaceuticals, Inc.
$130
Genentech USA, Inc.
$101
ARRAY BIOPHARMA INC
$72
PFIZER INC.
$68
Regeneron Healthcare Solutions, Inc.
$64
SpringWorks Therapeutics, Inc.
$50
Exelixis Inc.
$48
Kite Pharma, Inc.
$47
Astellas Pharma US Inc
$35
Eisai Inc.
$32
Blueprint Medicines Corporation
$30
PharmaEssentia USA Corporation
$29
Merck Sharp & Dohme LLC
$27
Alexion Pharmaceuticals, Inc.
$26
Agios Pharmaceuticals, Inc.
$25
Celgene Corporation
$24
Fennec Pharmaceuticals, Inc.
$21
Tempus AI, Inc
$20
GlaxoSmithKline, LLC.
$18
GENZYME CORPORATION
$14
Top 3 companies account for 33.1% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$1,148
Novartis Pharmaceuticals Corporation
$717
Pharmacyclics LLC, An AbbVie Company
$429
Merck Sharp & Dohme Corporation
$368
PFIZER INC.
$320
Amgen Inc.
$262
Celgene Corporation
$243
GENZYME CORPORATION
$238
AbbVie Inc.
$230
Genentech USA, Inc.
$196
Foundation Medicine, Inc.
$189
Astellas Pharma US Inc
$169
PharmaEssentia USA Corporation
$168
ViiV Healthcare Company
$168
Teva Pharmaceuticals USA, Inc.
$166
Regeneron Healthcare Solutions, Inc.
$160
Boehringer Ingelheim Pharmaceuticals, Inc.
$156
Janssen Biotech, Inc.
$154
ABBVIE INC.
$141
AstraZeneca Pharmaceuticals LP
$137
Regeneron Pharmaceuticals, Inc.
$130
Karyopharm Therapeutics Inc.
$129
Pharmacyclics LLC, an AbbVie Company
$128
EUSA Pharma (US) LLC
$116
Exelixis Inc.
$108
Seattle Genetics, Inc.
$105
EMD Serono, Inc.
$105
Daiichi Sankyo Inc.
$91
Seagen Inc.
$79
Blueprint Medicines Corporation
$74
ARRAY BIOPHARMA INC
$72
Lilly USA, LLC
$59
Immunocore Limited
$54
Gilead Sciences, Inc.
$54
Kyowa Kirin, Inc.
$53
Bayer HealthCare Pharmaceuticals Inc.
$52
MEDIVATION FIELD SOLUTIONS LLC
$52
SpringWorks Therapeutics, Inc.
$50
Agios Pharmaceuticals, Inc.
$48
Otsuka America Pharmaceutical, Inc.
$47
Kite Pharma, Inc.
$47
Eisai Inc.
$46
AVEO Pharmaceuticals, Inc.
$45
Partner Therapeutics, Inc.
$43
Janssen Pharmaceuticals, Inc
$42
Array BioPharma Inc.
$42
Puma Biotechnology, Inc.
$42
Dova Pharmaceuticals
$40
GlaxoSmithKline, LLC.
$36
Spectrum Pharmaceuticals Inc.
$35
Clovis Oncology, Inc.
$33
Takeda Pharmaceuticals U.S.A., Inc.
$28
Merck Sharp & Dohme LLC
$27
Alexion Pharmaceuticals, Inc.
$26
AMAG Pharmaceuticals, Inc.
$24
BeiGene USA, Inc.
$23
TESARO, Inc.
$22
Sun Pharmaceutical Industries Inc.
$22
MorphoSys, US Inc.
$21
Fennec Pharmaceuticals, Inc.
$21
TerSera Therapeutics LLC
$21
Tempus AI, Inc
$20
SOBI, INC
$18
Secura Bio, Inc.
$17
United Therapeutics Corporation
$16
Sirtex Medical Inc
$15
AbbVie, Inc.
$14
Ipsen Biopharmaceuticals, Inc
$12
Top 3 companies account for 28.1% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AYVAKIT · Abraxane · Alecensa · Aliqopa · Avastin · BAVENCIO · BENDEKA · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · Braftovi · CABOMETYX · CALQUENCE · CREON · CYRAMZA · Cabometyx · Cresemba · DARZALEX · DOVATO · Doptelet · ELIQUIS · EMPLICITI · EPKINLY · ERBITUX · FARESTON · FERAHEME · FOTIVDA · FOUNDATIONONE · Fabhalta · Farydak · Folotyn · GAVRETO · GILOTRIF · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · Inrebic · JADENU · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · Kyprolis · LENVIMA · LIBTAYO · LYNPARZA · Lenvima · Leukine · MEKINIST · MONJUVI · MYLOTARG · Nerlynx · Neulasta · Nplate · Nubeqa · OGSIVEO · OJJAARA · OPDIVO · OPDUALAG · ORENITRAM · Odomzo · PADCEV · PLUVICTO · POTELIGEO · PROMACTA · PYRUKYND · Pedmark · Perjeta · Prolia · Revlimid · Rubraca · SAMSCA · SANCUSO · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · SUTENT · Sylvant · TABRECTA · TASIGNA · TECENTRIQ · Turalio · ULTOMIRIS · VENCLEXTA · VOTRIENT · Venclexta · Vitrakvi · XALKORI · XARELTO · XOSPATA · XPOVIO · XTANDI · Xermelo · YERVOY · Yescarta · ZEJULA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
18
Per 100K population
0.5
County median income
$102,285
Nearest hospital
UC SAN DIEGO HEALTH HILLCREST - HILLCREST MED CTR
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Bollin is a mixed practice specialist, with above-average Medicare volume (top 18% in CA), with low-engagement industry engagement, with 16 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Bollin experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Bollin performed 14,401 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bollin receive payments from pharmaceutical companies?
Yes. Dr. Bollin received a total of $8,163 from 68 companies across 394 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bollin's costs compare to other medical oncologists in San Diego?
Dr. Bollin's average Medicare payment per service is $46. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bollin) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in San Diego
Browse medical oncologists in San Diego ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in CA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in CA
Which CA medical oncologists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Pharmacyclics LLC, An AbbVie Company Payments to Doctors
See all physicians who received payments from Pharmacyclics LLC, An AbbVie Company.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology